Bank of New York Mellon Corp grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,881,405 shares of the biopharmaceutical company’s stock after buying an additional 310,607 shares during the quarter. Gilead Sciences accounts for about 0.6% of Bank of New York Mellon Corp’s portfolio, making the stock its 24th largest holding. Bank of New York Mellon Corp owned about 2.36% of Gilead Sciences worth $2,185,784,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Waldron LP increased its position in Gilead Sciences by 20.4% during the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after purchasing an additional 1,752 shares in the last quarter. WealthTrust Axiom LLC increased its position in Gilead Sciences by 20.3% in the 1st quarter. WealthTrust Axiom LLC now owns 19,541 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 3,303 shares during the period. Pegasus Partners Ltd. increased its position in Gilead Sciences by 36.2% in the 1st quarter. Pegasus Partners Ltd. now owns 18,724 shares of the biopharmaceutical company’s stock valued at $1,272,000 after acquiring an additional 4,980 shares during the period. Conning Inc. increased its position in Gilead Sciences by 241.0% in the 1st quarter. Conning Inc. now owns 120,564 shares of the biopharmaceutical company’s stock valued at $8,189,000 after acquiring an additional 85,212 shares during the period. Finally, Dowling & Yahnke LLC increased its position in Gilead Sciences by 1.0% in the 1st quarter. Dowling & Yahnke LLC now owns 48,601 shares of the biopharmaceutical company’s stock valued at $3,301,000 after acquiring an additional 492 shares during the period. Institutional investors own 73.88% of the company’s stock.
A number of equities research analysts have recently commented on the stock. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Thursday, August 31st. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 target price on shares of Gilead Sciences in a report on Thursday, August 31st. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective for the company in a report on Friday, October 13th. Credit Suisse Group restated an “outperform” rating and set a $85.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $85.64.
In other news, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the transaction, the executive vice president now directly owns 106,113 shares in the company, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold a total of 446,819 shares of company stock valued at $36,338,919 in the last quarter. Insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/27/gilead-sciences-inc-gild-position-increased-by-bank-of-new-york-mellon-corp.html.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at 77.88 on Friday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a 50-day moving average price of $82.38 and a 200 day moving average price of $72.98. The stock has a market capitalization of $101.71 billion, a P/E ratio of 8.46 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 EPS. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.79 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.67%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.